AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 15.13 |
Market Cap | 12.73B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 0.77 |
PE Ratio (ttm) | 19.84 |
Forward PE | n/a |
Analyst | Buy |
Ask | 15.29 |
Volume | 844,220 |
Avg. Volume (20D) | 1,290,755 |
Open | 15.31 |
Previous Close | 15.31 |
Day's Range | 15.15 - 15.35 |
52-Week Range | 13.43 - 16.89 |
Beta | undefined |
About RDY
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finish...
Analyst Forecast
According to 1 analyst ratings, the average rating for RDY stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 11.26% from the latest price.
Next Earnings Release
Analysts project revenue of $964.48M, reflecting a 11.24% YoY growth and earnings per share of 0.19, making a -5.00% decrease YoY.
2 months ago · seekingalpha.com
Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call TranscriptDr. Reddy's Laboratories Limited (NYSE:RDY ) Q2 2025 Earnings Conference Call November 5, 2024 9:00 AM ET Company Participants Richa Periwal - Head of Investor Relations MV Narasimham - Chief Financia...